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S U M M A R Y
Background: Clinical reasoning utilizing certain symptoms and scores has not proven to be a reliable
decision-making tool to determine whether or not to suspect a group A Streptococcus (GAS) infection in
the patient presenting with a sore throat. Culture as the so-called ‘gold standard’ is impracticable
because it takes 1 to 2 days (and even longer in remote locations) for a result, and thus treatment
decisions will be made without the result available. Rapid diagnostic antigen tests have demonstrated
sufﬁcient sensitivities and speciﬁcities in detecting GAS antigens to identify GAS throat infections.
Methods: Throat swab samples were collected from patients attending the Mount Isa Hospital
emergency department for a sore throat; these samples were compared to swab samples collected from
healthy controls who did not have a sore throat. Both groups were aged 3–15 years. All swab samples
were analyzed with a point-of-care test (Alere Test Pack +Plus with OBC Strep A). The etiologic predictive
value (EPV) of the throat swab was calculated.
Results: The 95% conﬁdence interval for positive EPV was 88–100% and for negative EPV was 97–99%,
depending on assumptions made.
Conclusion: This study demonstrates that the point-of-care test Alere Test Pack +Plus Strep A has a high
positive predictive value and is able to rule in GAS infection as long as the proportion of carriers is low.
Also the negative predictive value for ruling out GAS as the etiologic agent is very high irrespective of the
carrier rate. Hence, this test is always useful to rule out GAS infection.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
With an incidence of 3–13 cases per 100 patient-years, Group A
Streptococcus (GAS) pharyngitis is a common presentation, not
only in primary health care but also in emergency departments.1
Amongst all patients presenting with a sore throat, the incidence of* Corresponding author at: Associate Professor Ulrich Orda, Mount Isa Hospital
Emergency Department 30 Camooweal Street, Mount Isa, QLD, 4825, Australia.
E-mail address: ulrich.orda@gmail.com (U. Orda).
http://dx.doi.org/10.1016/j.ijid.2016.02.002
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).GAS infection reported in the literature ranges from almost 0% to
40%.2,3 Both the incidence of acute presentations and the severity
may vary over time, and infections may occur in clusters.4
GAS pharyngitis is a main cause of acute rheumatic fever (ARF)
and rheumatic heart disease.5Whilst the absolute global burden of
GAS disease is not exactly known, estimated annual numbers of
rheumatic heart disease cases worldwide of approximately
2 400 0006 to 12 000 0007 have been reported. North Queensland,
Australia, has one of the highest incidences of ARF and rheumatic
heart disease in the world, especially within the indigenousciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Etiologic predictive value (EPV) of the testsa
Estimated sensitivity
to ﬁnd GAS
Estimation
of thetab
Positive
EPV
Negative
EPV
0.97 1.0 98 (88–100)% 99 (98–99)%
0.95 1.0 98 (88–100)% 98 (97–99)%
0.97 1.1 98 (88–100)% 99 (98–99)%
0.95 1.1 98 (88–100)% 98 (97–99)%
GAS, group A Streptococcus.
a The EPV of tests states the probability that the test ﬁnding is linked to
symptoms/signs while considering symptomatic carriers ill from another agent
(such as a virus).
b Theta is the estimated prevalence of GAS among symptomatic patients ill from
something other than GAS, usually a virus; 1.0 means the prevalence is the same as
among the healthy individuals and 1.1 means a 10% higher prevalence than in
asymptomatic healthy individuals.
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100 000 population.5,8 This is due to a high percentage of residents
in this region living in remote communities, often in varying
degrees of poverty and crowding, and is consistent with ﬁndings in
the Northern Territory, Australia.9
Whilst there is increasing suspicion and some evidence that
ARF may also be related to chronic skin sores (pyoderma),5 patients
having a sore throat remain the main focus.
Identifying the individual patient presenting with a sore throat
as having a GAS infection is more challenging than it seems on ﬁrst
sight, not even taking into account whether all positive GAS results
actually represent an acute bacterial infection.10 Utilizing clinical
decision rules based solely on symptoms and signs, such as the
Centor criteria and World Health Organization criteria, does not
appear to be reliable enough to clarify whether the infective agent
is GAS or not, and thus whether to treat with antibiotics or not.10,11
The resulting problems are an untreated GAS infection that may
lead to ARF, and more often, the unnecessary prescription of
antibiotics leading to side effects as well as the potential of bacteria
developing antibiotic resistance.
Throat culture has been recommended as an aide for treatment
decisions.1,12 However, it has been shown that the 1–2 days of
delay until the result is available results in the decision being made
without considering the outcome of the culture.13,14 Furthermore,
in the setting in which a large number of patients travel several
hundred kilometers to see a doctor and where there is limited
phone reception, it is difﬁcult to organize re-presentation or
follow-up of the results including treatment modiﬁcations.
An excellent solution for this dilemma would be a bedside rapid
antigen detection test (RADT) for GAS that provides a positive or
negative result within 5–10 min, thus directly inﬂuencing the
treatment decision. Such RADTs have been evaluated previously
using throat culture as the gold standard and initially showed
insufﬁcient sensitivity and speciﬁcity.12,15 Later studies have
provided evidence that the sensitivity of GAS RADT is equal or
superior to culture, and speciﬁcity close to 100%.16,17,18
The aim of this study was to evaluate the ability of a RADT to
rule in or out a true link between the symptom of a sore throat and
the test outcome while considering the potential of GAS carriers.
2. Materials and methods
Two groups of participants were recruited consecutively. The
ﬁrst comprised healthy controls. These were children aged 3–15
years presenting consecutively at the Mount Isa Hospital emergency
department (ED) in northwest Queensland, Australia, for reasons
other than infection, thus ensuring that a positive GAS RADT result in
this group would represent asymptomatic carriage. The second
group comprised patients with a sore throat. These were children
aged 3–15 years presenting consecutively at the Mount Isa Hospital
ED in northwest Queensland, Australia, for a sore throat. None of
these children had previously had rheumatic fever.
Once consent was obtained, a throat swab was collected from
each child. This was done using the Dacron swab provided with the
test kit. The swab was sealed in a specimen bag, together with a
data collection sheet and a signed consent form, put in an envelope,
and stored in a refrigerator at approximately 6 8C outside the
clinical area.
The study team processed the swabs within 72 h using the Alere
Test Pack +Plus with OBC Strep A kit (Alere, Waltham, MA, USA).
This test kit has shown a 95%19 to 97%17 sensitivity (the
manufacturer quotes a 97% sensitivity) and a speciﬁcity of 95%17
to 100%19 to detect GAS. In this study the outcomes were compared
with the assumption that the sensitivity of the point-of-care test
was 95% and with the assumption that the sensitivity was 97%. The
treating clinician was blinded to the point-of-care test result.The intention was to collect up to 200 samples in each group,
with an interim analysis after approximately 50% of samples had
been obtained.
2.1. Statistical analysis
The etiologic predictive value (EPV) is a statistical method
developed to link symptoms and signs to test ﬁndings, hence
linking potential etiologic agents such as a bacterium, while taking
carriers into consideration.20 To calculate the EPV, it is necessary to
have the proportion of positive tests among patients, the
proportion of positive tests among a healthy control population,
and the sensitivity of the test to ﬁnd what it is designed to look for.
This enables the positive and negative predictive values, including
95% conﬁdence intervals, to be calculated in a situation where a
gold standard for comparison is not present or is questionable and
the population prevalence of GAS is previously unknown.20 The
inﬂuence of different assumptions for theta (the assumed ratio
between the proportion of carriers of GAS among healthy
individuals and those with a sore throat caused by a virus) was
also explored.21
Ethics approval was granted by the Townsville Hospital and
Health Service, Human Research and Ethics Committee (HREC/13/
QTHS/260).
3. Results
From June 30, 2014 to February 27, 2015, 248 throat swabs
were collected and examined within 72 h. Two parents refused
the collection of swabs for the purpose of this study. Out of the
101 patients presenting with a sore throat, 26 (26%) tested
positive for GAS. Only one (0.7%) of the 147 control patients had
a positive test result. Statistical analysis showed both the
positive and negative EPV to be high (Table 1). The conﬁdence
intervals in this interim analysis were deemed to be narrow
enough and hence further data collection was cancelled.
4. Discussion
The main ﬁnding of this study was that both the positive and
negative EPV indicated that this RADT can be used to both rule in
and rule out a link between symptoms and GAS for the study
population. However, this conclusion may not be valid in other
circumstances where the prevalence of carriers or the proportion
of patients having GAS is different. The incidence of GAS
colonization of the pharynx in asymptomatic patients reported
in the literature is controversial and ranges from less than 2% to
11%.22 Some authors refer to GAS carriers as sources for recurrent
infections and deem the rate of asymptomatic carriers to be as high
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Figure 1. Variation in the positive etiologic predictive value depending on the
carrier rate and prevalence of GAS among patients, assuming a sensitivity of the test
of 95%, as with a rapid antigen detection test (reproduced with the kind permission
of R. Gunnarsson21).
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Figure 2. Variation in the negative etiologic predictive value depending on the
carrier rate and prevalence of GAS among patients, assuming a sensitivity of the test
of 95%, as with a rapid antigen detection test (reproduced with kind permission of R.
Gunnarsson21).
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Furthermore, the proportion of patients having GAS may vary in
different settings from close to zero up to 40%.2,3 In unselected
cases in primary health care or similar settings it would most often
be between 5% and 25%.
Clinical decision rules have not shown appropriate predictive
values to be considered sufﬁcient for clinical decision-making
alone as to whether or not to treat a sore throat as a GAS
infection.7,10,24 Focusing on patients with severe pharyngitis alone
may increase the positive predictive value of a decision-making
rule, but would focus only on a small subgroup of patients.
Culture has historically been considered the gold standard, not
only for diagnostics in clinical practice, but also for rating other
diagnostic methods.1,24,25 However it has been shown that modern
GAS RADTs have similar or better sensitivity than culture,17,18
especially when assessed using PCR testing, the gold standard in
many other areas of diagnostics of infectious diseases. PCR tests
have shown positive results for patient samples testing positive
with a RADT but negative with culture,26 demonstrating that some
RADTs are more sensitive than culture when assessed against PCR
as the gold standard.26,27
Whilst the beneﬁt of a bedside test for decision-making is
widely acknowledged,14,28 the beneﬁt of older generation tests has
been controversial,14 demonstrating a lower sensitivity for a small
inoculum size.29 However it has been found that even the
utilization of older generations of bedside tests in the ED and
other acute care settings is signiﬁcantly better than clinical
judgment alone,24,30 especially in combination with history,
examination, and a clinical decision rule.28
The sensitivity/speciﬁcity and predictive values of several
RADTs have been deemed sufﬁcient for diagnosis and management
in other studies,1,31 including the test utilized for the present
study, which has shown excellent predictive values.
This study is the ﬁrst to calculate EPV for a RADT in the setting of
sore throat patients. The inﬂuence of different assumptions was
tested, such as the sensitivity of the test and theta. The
assumptions most likely to reﬂect the reality would be a sensitivity
of RADT to detect the presence of GAS of 95–97% with a theta of 1.21
Thus, the positive EPV would be 98 (88–100)% and subsequent
negative EPV 98–99 (97–99)%. Hence, a negative RADT would rule
out the possibility of a sore throat being caused by GAS with a
probability of 97%.
A strength of this study was the use of an established low-cost
RADT with a high sensitivity and speciﬁcity. This test should
normally be performed in the clinic or ED by a doctor (general
practitioner, registrar, or emergency physician) or a nurse,
producing a result within minutes. The tests were analyzed in
batches in this study and the outcomes were not given to the
treating doctor. The reason for this was that the aim of the study
was to establish predictive values of tests rather than the actual
inﬂuence that this RADT might have on decision-making.
The direct ﬁndings of this study are applicable to unselected
presentations of children aged 3–15 years having a sore throat,
with a low carrier rate of GAS and around 25% of children with a
sore throat having a positive test for GAS. It can be shown that the
positive EPV remains quite high as long as the proportion of
carriers remains very low (Figure 1). The positive EPV for this RADT
becomes unreliable when the carrier rate of GAS increases
(Figure 1). The negative EPV usable to rule out a link between
symptoms and GAS always remains high, irrespective of the carrier
rate of GAS and for any reasonable change in the proportion of
patients with a sore throat having GAS (Figure 2). Therefore when
utilizing the EPV to rate the post test probability of GAS infection,
the result is transferable not only to different regions once the
numbers of true infections and asymptomatic carriers are
established, but also to every age group.The RADTs are a signiﬁcant step forward in correctly diagnosing
sore throat and greatly help to prevent unnecessary antibiotic
prescription.10 In Australia they are relatively cheap (AUD 4/USD 3/
EUR 2.70) compared to culture (AUD 29/USD 21.70/EUR 19.30).
PCR tests have even better test performance, with sensitivity and
speciﬁcity close to 100%, but are more difﬁcult to use and too
expensive to be used for unselected patients with a sore throat
(varying cost depending on the system used). However, this may
change in the future.
In conclusion, it can be shown mathematically that a point-of-
care test like the Alere Test Pack +Plus Strep A is always useful to
rule out a link between symptoms of a sore throat and GAS. Its
ability to rule in a link between symptoms and GAS depends on the
carrier rate of GAS. Having the results within 5–10 min makes it
ideal for guiding treatment decisions in unselected presentations
of patients with a sore throat.
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